Document:

Third Amendment dated as of December 16, 2009

 Exhibit 10.1 
 THIRD AMENDMENT 
 This Third Amendment dated as of
December 16, 2009 (this “Amendment”) relates to the Three Year Revolving Credit Facility Agreement dated as of February 17, 2009 (as previously amended, the “Credit Agreement”) among MEAD JOHNSON NUTRITION
COMPANY (“Holdings”), MEAD JOHNSON & COMPANY (“MJC”), various lenders and JPMORGAN CHASE BANK, N.A., as administrative agent. Capitalized terms used but not defined herein have the meanings assigned to such
terms in the Credit Agreement. 
 WHEREAS, pursuant to the First Amendment and Consent dated as of November 5, 2009 (the
“First Amendment”) among Holdings, MJC, the Required Lenders and the Administrative Agent, (i) Holdings became a Borrower under the Credit Agreement (succeeding to all rights and obligations previously held by MJC in its
capacity as a Borrower thereunder) and (ii) MJC became an Original Guarantor under the Credit Agreement; 
 WHEREAS,
Holdings has requested that the Lenders release MJC from its obligations as an Original Guarantor; and 
 WHEREAS, concurrently
with such release, MJC shall be released from its guarantee of the obligations of Holdings under the Private Placement Notes (as defined in the First Amendment); 
 NOW THEREFORE, the parties hereto agree as follows: 
 Section 1
RELEASE. The Lenders agree that, concurrently with the effectiveness hereof pursuant to Section 4, MJC shall be released from its obligations as an Original Guarantor under the Credit Agreement and shall no longer be a guarantor
of the obligations of Holdings or any Subsidiary Borrower under or in connection with the Credit Agreement; provided, that if at any time the corporate credit rating of Holdings is no longer (i) at least BBB- by Standard &
Poor’s Ratings Service or (ii) at least Baa3 by Moody’s Investors Service, Inc., then MJC shall guarantee (and shall be deemed to guarantee) the Borrower Obligations of all of the Borrowers in full as an Original Guarantor and
MJC’s obligations as an Original Guarantor shall be automatically reinstated without the need for any further action. The Lenders agree that the Administrative Agent may, and direct the Administrative Agent to, execute and deliver such
documents as Holdings or MJC may reasonably request to evidence such release and the termination of MJC’s obligations as an Original Guarantor. 
 Section 2 AMENDMENTS. In furtherance of Section 1 above, the parties hereto agree that concurrently with the effectiveness hereof, the Credit Agreement shall be amended as
set forth in Sections 2.1 and 2.2. 
 2.1 Amended Definitions. The definitions of “Guarantor” and
“Original Guarantors” in Section 1.1 are amended in their entirety to read as follows, respectively: 
 “Guarantor” shall mean the collective reference to Holdings and the Subsidiary Guarantors. 

 “Original Guarantors” shall mean (i) with respect to
the obligations of any Borrowing Subsidiary, Holdings, and (ii) under the circumstances described in the Third Amendment to this Agreement, dated as of December 16, 2009, the Company. 
 2.2 Amendment to Restrictive Agreements Covenant. (a) Section 5.15(a) is amended by (x) deleting “and (iii)”
where it appears therein and substituting “, (iii)” therefor; and (y) inserting the following immediately before the period at the end thereof: 
 and (iv) customary non-assignment provisions in leases or other agreements entered in the ordinary course of business and consistent with past practices. 
 (b) Section 5.15(b)(iii) is amended by (x) deleting “and (F)” where it appears therein and substituting “,
(F)” therefor; and (y) inserting the following immediately before the period at the end thereof: 
 and
(G) customary non-assignment provisions arising in connection with any acquisition agreement. 
 Section 3
REPRESENTATIONS AND WARRANTIES. Holdings and MJC represent and warrant to the Lenders and the Administrative Agent that (a) the representations and warranties set forth in Article III of the Credit Agreement are true and correct in all
material respects on the date hereof, except to the extent such representations and warranties expressly relate to an earlier date, in which case such representations and warranties were true and correct as of such earlier date and
(b) concurrently with the effectiveness hereof pursuant to Section 4, MJC’s guaranty of the obligations of Holdings under the Private Placement Notes shall terminate and be of no further force or effect. 
 Section 4 EFFECTIVENESS. This Amendment shall become effective when the Administrative Agent has received counterparts
hereof signed by Holdings, MJC and all Lenders. 
 Section 5 MISCELLANEOUS. 
 5.1 Continuing Effectiveness. Except to the extent expressly set forth herein, the Credit Agreement and the other Loan Documents
remain in full force and effect and are ratified, approved and confirmed in all respects. After the effectiveness of this Amendment, all references in the Credit Agreement and the other Loan Documents to “Credit Agreement” or similar terms
shall refer to the Credit Agreement as amended hereby. 
 5.2 Fees. Holdings agrees to pay to the Administrative Agent,
for the account of each Lender, an amendment fee equal to 0.03% of such Lender’s outstanding Commitment, which amendment fee shall be payable on the date this Amendment becomes effective. 
 5.3 Counterparts. This Amendment may be executed in multiple counterparts, each of which shall constitute an original but all of
which taken together shall constitute but one

  

 2 

 
contract. A counterpart hereof, or signature page hereto, delivered to the Administrative Agent by facsimile or e-mail shall be effective as delivery of an original manually-signed counterpart.

 5.4 Incorporation by Reference. The provisions of Sections 8.5, 8.11, 8.13 and 8.14 of the
Credit Agreement are incorporated herein by reference as if fully set forth herein, mutatis mutandis. 
 5.5
Governing Law. THIS AMENDMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.  
 [Signature Pages Follow] 
  

 3 

 IN WITNESS WHEREOF, the parties hereto have signed this Amendment as of the date first above
written. 
  

			
	MEAD JOHNSON NUTRITION COMPANY
		
	By:	 	       /s/ Kevin Wilson

		 	 Name: Kevin Wilson
 Title:
Vice President and Treasurer

		
	By:	 	       /s/ Stanley Burhans

		 	Name: Stanley Burhans
		 	Title: Vice President and Controller
	
	MEAD JOHNSON & COMPANY
		
	By:	 	       /s/ Kevin Wilson

		 	 Name: Kevin Wilson
 Title:
Vice President and Treasurer

  

 [Signature Page to Mead Johnson Third Amendment] 

			
	JPMORGAN CHASE BANK, N.A., as Administrative Agent and as a Lender
		
	By:	 	       /s/ Barbara R. Marks

		 	Name: BARBARA R. MARKS
		 	Title: EXECUTIVE DIRECTOR

  

 [Signature Page to Mead Johnson Third Amendment] 

			
	Citibank, N.A., as a Lender
		
	By:	 	       /s/ Mark R. Floyd

		 	Name: Mark Floyd
		 	Title: Vice President

  

 [Signature Page to Mead Johnson Third Amendment] 

			
	Bank of America, N.A., as a Lender
		
	By:	 	       /s/ David L. Catherall

		 	Name: David L. Catherall
		 	Title: Senior Vice President

  

 [Signature Page to Mead Johnson Third Amendment] 

			
	Bank of Tokyo-Mitsubishi UFJ Trust Company, as a Lender
		
	By:	 	       /s/ Lillian Kim

		 	Name: LILLIAN KIM
		 	Title: Vice President

  

 [Signature Page to Mead Johnson Third Amendment] 

			
	CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH (f/k/a CREDIT SUISSE, CAYMAN ISLANDS BRANCH), as a Lender
		
	By:	 	       /s/ Karim Blasetti

		 	Name: Karim Blasetti
		 	Title: Vice President
		
	By:	 	       /s/ Ilya Ivashkov

		 	Name: Ilya Ivashkov
		 	Title: Associate

  

 [Signature Page to Mead Johnson Third Amendment] 

			
	 MORGAN STANLEY BANK, N.A.,
 as a Lender

		
	By:	 	       /s/ Ryan Vetsch

		 	Name: Ryan Vetsch
		 	Title: Authorized Signatory

  

 [Signature Page to Mead Johnson Third Amendment] 

			
	ROYAL BANK OF CANADA, as a Lender
		
	By:	 	       /s/ Gordon MacArthur

		 	Name: Gordon MacArthur
		 	Title: Authorized Signatory

  

 [Signature Page to Mead Johnson Third Amendment] 

			
	UBS Loan Finance LLC, as a Lender
		
	By:	 	       /s/ Irja R. Otsa

		 	Name: Irja R. Otsa
		 	Title: Associate Director
		
	By:	 	       /s/ April Varner - Nanton

		 	Name: April Varner - Nanton
		 	Title: Director

  

 [Signature Page to Mead Johnson Third Amendment]Amendment No. 3 to Agreement and Plan of Merger

 Exhibit 10.1 
 AMENDMENT NO. 3 TO AGREEMENT AND PLAN OF MERGER 
 THIS AMENDMENT NO. 3 TO AGREEMENT AND PLAN OF MERGER (this
“Amendment”) is made and entered into as of December 17, 2009, by and among LIGAND PHARMACEUTICALS INCORPORATED, a Delaware corporation (“Parent”);
NEON SIGNAL, LLC, a Delaware limited liability company and a wholly-owned Subsidiary of Parent (“Merger Sub”); and NEUROGEN CORPORATION, a Delaware corporation (the
“Company”). This Amendment is made with regard to the Agreement and Plan of Merger dated August 23, 2009, by and among Parent, Merger Sub and the Company (as previously amended, the “Agreement”). 
 1. The Agreement is hereby amended by changing the definition of “Determination Date” in Article I of the Agreement to read in
full as follows: 
 “Determination Date” shall mean December 15, 2009. 
 2. The Agreement is hereby amended by changing Section 2.06(a)(iii) of the Agreement to read in full as follows: 
 (iii) except as provided in clauses (i) and (ii) above, each issued and outstanding Company Share (other than Dissenting Shares)
shall be converted, subject to Section 2.09, into the right to receive (A) a portion of a validly issued, fully paid and nonassessable share of common stock, par value $0.001 per share, of Parent equal to the Exchange Ratio, including the
associated rights under the Parent Rights Agreement (the “Parent Common Stock”); provided, that the maximum number of shares of Parent Common Stock that Parent shall be required to issue pursuant to this Section 2.06(a)(iii) shall not
exceed the Maximum Amount, (B) in the event the Aplindore Program is sold by the Company before the Effective Time, an amount in cash and/or a number of shares of third-party stock, as the case may be, equal to the Aplindore Program
Consideration which has been received as of the Effective Time divided by the total number of Outstanding Company Shares, (C) in the event the Real Estate is sold by the Company before the Effective Time, an amount in cash equal to the Real
Estate Consideration which has been received as of the Effective Time divided by the total number of Outstanding Company Shares, (D) one Aplindore CVR (unless the Aplindore Program is sold by and all proceeds thereof are received by the Company
before the Effective Time, or the Aplindore Program is terminated by the Company before the Effective Time), (E) one H3 CVR, (F) one Merck CVR, (G) one Real Estate CVR (unless the Real Estate is sold by and all proceeds thereof are
received by the Company before the Effective Time), and (H) an amount in cash equal to $600,000 divided by the total number of Outstanding Company Shares (collectively, the “Merger Consideration”); 
 3. The Agreement is hereby amended by changing the first sentence of Section 2.08(a) of the Agreement to read in full as follows:

 Before the Effective Time: (i) Parent shall select a bank or trust company (reasonably acceptable to the Company) to act
as exchange agent with respect to the payment of the Merger Consideration (the “Exchange Agent”); and (ii) Parent (or, as applicable, the Company) shall deposit with the Exchange Agent the Section 2.06(a)(iii)(H) cash component
of the Merger Consideration, certificates representing the shares of Parent Common Stock, the Aplindore Program Consideration (to the extent already received by the Company) in the event the Aplindore Program is sold by the Company at or before the
Effective Time, the Real Estate Consideration (to the extent already received by the Company) in the event the Real Estate is sold by the Company at or before the Effective Time, sufficient to enable the Exchange Agent to make payments pursuant to
Section 2.06 and Section 2.09 to the holders of Outstanding Company Shares. 
 4. The Agreement is hereby amended by
changing Section 7.01(b) of the Agreement to read in full as follows: 
 (b) by either Parent or the Company
if the Company Stockholder Approval shall not have been obtained by reason of the failure to obtain the required vote at the Special Meeting or at any postponement or adjournment thereof by December 31, 2009; 

 5. The Agreement is hereby amended by changing Section 7.01(c) of the Agreement to read
in full as follows: 
 (c) by Parent or the Company at any time after December 31, 2009 (the “Outside
Date”) if the Effective Time shall not have occurred on or before the Outside Date (provided that the right to terminate this Agreement pursuant to this Section 7.01(c) shall not be available to any party where the failure of such party
(or any Affiliate or Representative of such party) to fulfill any obligation under this Agreement or any voting agreement has resulted in the failure of the Effective Time to have occurred on or before the Outside Date; 
 6. The Agreement is hereby amended by deleting Section 7.01(i) of the Agreement. 
 7. The Agreement is hereby amended by changing Section 7.03(b) of the Agreement to read in full as follows: 
 (b) If this Agreement is validly terminated by Parent pursuant to Section 7.01(e), then, within two (2) Business
Days after such termination, the Company shall pay the Termination Fee to Parent. 
 8. Except as expressly set forth herein,
the Agreement remains unchanged and in full force and effect. 
 9. This Amendment may be executed in counterparts, each of
which shall be deemed to be an original, and all of which taken together shall be deemed to constitute one and the same instrument. The parties agree that delivery of an executed counterpart of a signature page of this Amendment electronically or by
facsimile shall be effective as delivery of a manually executed counterpart of this Amendment. 
 IN WITNESS WHEREOF, Parent,
Merger Sub and the Company have caused this Amendment No. 3 to be executed as of the date first written above. 
  

					
	LIGAND PHARMACEUTICALS INCORPORATED
		
	By:	 	 /s/ John L. Higgins

	Name:	 	 John L. Higgins

	Title:	 	 CEO and President

	
	NEON SIGNAL, LLC
		
	By:	 	Ligand Pharmaceuticals Incorporated, its Member-Manager
			
		 	By:	 	 /s/ John L. Higgins

		 	Name:	 	 John L. Higgins

		 	Title:	 	 CEO and President

	
	NEUROGEN CORPORATION
		
	By:	 	 /s/ Steve Davis

	Name:	 	 Steve Davis

	Title:	 	 President & CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]